Radium Ra 223 dichloride

(Xofigo)

Radium Ra 223 dichloride

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 1,100 kBq/mL (30 microcurie/mL))
Drug ClassAlpha particle-emitting radioactive therapeutic agents
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Xofigo (radium Ra 223 dichloride) Prescribing Information.2019Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines